News
VNRX
0.8902
+11.27%
0.0902
12 Health Care Stocks Moving In Tuesday's Intraday Session
VolitionRX (AMEX:VNRX) shares rose 33.6% to $0.8 during Tuesday's regular session. Palisade Bio (NASDAQ:PALI) stock increased by 29.81% during the session. Kintara Therapeutics and NKGen Biotech were among the losers.
Benzinga · 2d ago
Tuesday Sector Leaders: Diagnostics, Biotechnology Stocks
NASDAQ · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers ImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. Nuwellis shares increased by 24.1% and VolitionRX stock increased by 16.66% during the same time period. Losers Abeona Therapeutics and OncoCyte stock declined by 45.7% and 16.34% respectively.
Benzinga · 2d ago
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
Volition's Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S. And Europe through Antech. One in four dogs will be diagnosed with cancer. The test provides a rapid, accurate and cost-effective cancer screening tool for high-risk breeds and older dogs.
PR Newswire · 2d ago
Weekly Report: what happened at VNRX last week (0415-0419)?
Weekly Report · 3d ago
Thursday Sector Leaders: General Contractors & Builders, Diagnostics
NASDAQ · 04/18 16:01
Weekly Report: what happened at VNRX last week (0408-0412)?
Weekly Report · 04/15 11:58
Weekly Report: what happened at VNRX last week (0401-0405)?
Weekly Report · 04/08 12:04
Weekly Report: what happened at VNRX last week (0325-0329)?
Weekly Report · 04/01 12:01
Cantor Fitzgerald Reiterates Overweight on VolitionRX, Maintains $2.5 Price Target
Benzinga · 03/27 13:55
VolitionRX Is Maintained at Buy by EF Hutton
Dow Jones · 03/27 13:51
VolitionRX Price Target Maintained With a $4.50/Share by EF Hutton
Dow Jones · 03/27 13:51
EF Hutton Maintains Buy on VolitionRX, Maintains $4.5 Price Target
Benzinga · 03/27 13:43
Benchmark Co. Sticks to Its Hold Rating for VolitionRX (VNRX)
TipRanks · 03/27 12:26
Tuesday Sector Leaders: Grocery & Drug Stores, Diagnostics
NASDAQ · 03/26 16:36
VolitionRX reports FY results
Seeking Alpha · 03/26 05:52
VNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023
VolitionRX reported earnings per share of -11 cents for the fourth quarter of 2023. The company reported revenue of $243,973. This was 45.78% worse than the analyst estimate of $450,000. VolitionRx also reported results for the third quarter of 2018.
Investorplace · 03/26 00:52
VolitionRX Q4 EPS $(0.11), Inline, Sales $243.97K Miss $450.00K Estimate
VolitionRX reports quarterly losses of $0.11 per share which met the analyst consensus estimate. Company reported quarterly sales of $243.97 thousand which missed the analyst estimate of $450.00 thousand by 45.78%. The company reported a 15.38 percent increase in sales from the same period last year.
Benzinga · 03/25 20:28
VolitionRx Cash And Cash Equivalents As Of December 31, 2023, Totaled ~$20.7M
Recorded approximately $775,000 in revenue in 2023, up 153% over the prior year. Cash and cash equivalents as of December 31, 2023 totaled approximately $20.7 million. Received $13.0 million in milestone payments from Heska Corporation in December 2023. Volition will hold a conference call on March 26, 2024 to discuss the fourth quarter and full year of 2023 and upcoming milestones.
Benzinga · 03/25 20:11
Weekly Report: what happened at VNRX last week (0318-0322)?
Weekly Report · 03/25 12:04
More
Webull provides a variety of real-time VNRX stock news. You can receive the latest news about Volitionrx through multiple platforms. This information may help you make smarter investment decisions.
About VNRX
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.